Author Interviews, JAMA, Opiods, Pediatrics / 06.01.2020

MedicalResearch.com Interview with: [caption id="attachment_52629" align="alignleft" width="133"]Rachel H. Alinsky, MD, MPH Adolescent Medicine and Addiction Medicine Fellow Division of General Pediatrics and Adolescent Medicine Johns Hopkins University School of Medicine Dr. Alinsky[/caption] Rachel H. Alinsky, MD, MPH Adolescent Medicine and Addiction Medicine Fellow Division of General Pediatrics and Adolescent Medicine Johns Hopkins University School of Medicine MedicalResearch.com: What is the background for this study? Response: We know that over 4,000 adolescents and young adults between the ages of 15-24 are dying from an opioid overdose every year. Nonfatal opioid overdose has been identified as a potential touchpoint with the healthcare system when individuals can be drawn into treatment, yet very little is known about health care use following opioid overdose in youth. We were interested in figuring out the extent to which adolescents and young adults are receiving evidence-based treatment after an opioid overdose.
Alzheimer's - Dementia, Author Interviews, Brain Injury, Medical Imaging, UCSF / 06.01.2020

MedicalResearch.com Interview with: [caption id="attachment_52640" align="alignleft" width="180"]William G. Mantyh, MD Clinical Fellow, UCSF Memory and Aging Center Weill Institute for Neurosciences UCSF Dr. Mantyh[/caption] William G. Mantyh, MD Clinical Fellow, UCSF Memory and Aging Center Weill Institute for Neurosciences UCSF MedicalResearch.com: What is the background for this study? Response: Similar to Alzheimer’s disease (AD) and other dementing illnesses, Chronic Traumatic Encephalopathy (CTE) is a progressive neurodegenerative condition associated with abnormally folded tau protein in the brain. CTE is thought to be caused by exposure to repetitive head trauma, and recently has been the subject of intense media coverage given the frequency of CTE found in brains of deceased former American professional football players. CTE is almost impossible to confidently diagnose during life as the symptoms are diverse and vary from patient-to-patient. Symptoms can include impairments in memory, multi-tasking, behavioral/mood regulation, and movement. As there are no blood, imaging, or other tests for this disease, one active area of research is developing a test to help doctors diagnose this condition. As tau tangles in CTE are similar in many respects to those in Alzheimer’s disease, there was hope that PET tracers that detect tau in AD might also work in CTE. Flortaucipir (FTP) is probably the most widely used tau tracer in AD. Recent work has reported some signal from FTP-PET in symptomatic former NFL players and other patients at risk for CTE (Stern et al. New Engl Jour Med 2019; Lesman-Segev et al. Neuroimage Clinical 2019). The overall signal was lower than that observed in Alzheimer’s disease, and, in lieu of correlations with post-mortem findings, it was unclear how well FTP binds to tau pathology in CTE.
Addiction, Alcohol, Author Interviews, JAMA, Methamphetamine / 06.01.2020

MedicalResearch.com Interview with: [caption id="attachment_52664" align="alignleft" width="200"]Eric Dawson, PharmD Vice President, Clinical Affairs Millennium Health Dr. Dawson[/caption] Dr. Eric Dawson, PharmD Vice President, Clinical Affairs Millennium Health MedicalResearch.com: What is the background for this study? Response: The US Centers for Disease Control and Prevention has projected a drop in the number of overdose deaths for 2018; the first reported decline since 1990. They cite a decrease in prescription opioid deaths as the leading contributor to the overall reduction, but caution that deaths associated with synthetic opioids, primarily fentanyl, as well as stimulants appear to be increasing. In 2019, we reported a 798% increase in urine drug test positivity rates for nonprescribed fentanyl among results positive for methamphetamine and an 1850% increase among results positive for cocaine. In an effort to conduct ongoing surveillance of the polysubstance use landscape and help characterize these evolving trends in a more timely manner, we examined our UDT data as close to real-time as possible to observe trends in positivity for methamphetamine, cocaine, and heroin, with and without illicit fentanyl.
Author Interviews, Brigham & Women's - Harvard, Dermatology, Science / 05.01.2020

MedicalResearch.com Interview with: [caption id="attachment_52636" align="alignleft" width="180"]Dr. D. Branch Moody, MD Principal Investigator Associate Physician, Brigham and Women's Hospital Professor of Medicine, Harvard Medical School Dr. Moody[/caption] Dr. D. Branch Moody, MD Principal Investigator Associate Physician, Brigham and Women's Hospital Professor of Medicine, Harvard Medical School MedicalResearch.com: What is the background for this study? Is the CD1a molecule found on the skin's Langerhans cells? Response: With increasing industrialization worldwide, people apply cosmetics and other consumer products to the skin, leading to contact dermatitis, which is becoming increasingly common. Immunologists know that T cells participate in dermatitis reactions. However, T cells usually recognize and respond to antigens that are peptides rather than the non-peptide antigens that cause contact dermatitis.
Author Interviews, Gender Differences, JAMA, Occupational Health, Surgical Research / 05.01.2020

[caption id="attachment_52648" align="alignleft" width="200"]Matilda Anderson MBBS MBS General Surgery Trainee/Public Health/Researcher Footscray, Victoria, Australia Dr. Anderson[/caption] MedicalResearch.com Interview with: Matilda Anderson MBBS MBS General Surgery Trainee/Public Health/Researcher Footscray, Victoria, Australia MedicalResearch.com: What is the background for this study? Response: Female representation in the surgical workforce is increasing.  Previous studies have shown higher infertility rates and adverse pregnancy outcomes in this population.  We aimed to accurately define the available research in this area and provide some basic recommendations about how workplaces can support their female surgical residents and surgeons. On a more personal note- Dr Anderson is a female surgical resident and have seen countless pregnant colleagues remove themselves from operating rooms with the concern about how the conditions may affect their pregnancies.  Dr. Anderson met Associate Professor Goldman at Harvard University (a leading expert on occupational reproductive hazards) and collaborated to explore this area further.
Author Interviews, Johns Hopkins, NEJM, Weight Research / 02.01.2020

MedicalResearch.com Interview with: [caption id="attachment_52623" align="alignleft" width="230"]Mark P. Mattson, Ph.D. Adjunct Professor of Neuroscience Johns Hopkins University School of Medicine Dr. Mattson[/caption] Mark P. Mattson, Ph.D. Adjunct Professor of Neuroscience Johns Hopkins University School of Medicine  MedicalResearch.com: What is the background for this study? Response: The usual eating pattern of most people in modern societies is breakfast, lunch, dinner plus a snack(s) every day.   Animals used for most biomedical research – rats and mice – are usually fed ‘ad libitum’ (food is always available for them to eat).    During the past 25 years, myself and the many scientists who trained in my laboratory discovered that when rats or mice are fed intermittently such that they have no food every other day or eat only during a 4-6 hour time period each day, their overall health improves in many ways.  Animals on such intermittent fasting (IF) regimens exhibit signs of slowed aging and they live much longer than those fed ad libitum. The editors of the New England Journal of Medicine invited me and Rafa de Cabo (a former postdoc in my laboratory at the National Institute on Aging) to write this review article for two main reasons.   First, there have been a sufficient number of studies demonstrating the health benefits of IF in humans and knowledge of the underlying mechanisms to justify a review article.  Second, many physicians are being asked about IF by their patients and the physicians are not privy as to if they should recommend IF and how to prescribe specific IF eating patterns and follow-up to increase the likelihood that the patient will be successful in changing their eating pattern. 
Author Interviews, Brigham & Women's - Harvard, JAMA, OBGYNE, Pediatrics, Weight Research / 02.01.2020

MedicalResearch.com Interview with: [caption id="attachment_52619" align="alignleft" width="200"]Elvira Isganaitis, M.D., M.P.H. Pediatric Endocrinologist, Joslin Diabetes Center Assistant Professor of Pediatrics, Harvard Medical School Boston, MA 02215 Dr. Isganaitis[/caption] Elvira Isganaitis, M.D., M.P.H. Pediatric Endocrinologist, Joslin Diabetes Center Assistant Professor of Pediatrics, Harvard Medical School Boston, MA 02215 MedicalResearch.com: What is the background for this study? Response: The concept that a mother's nutrition prior to and during pregnancy is important for health outcomes in the offspring is now well accepted. For example, women intending to get pregnant must take prenatal vitamins, and are encouraged to attain a healthy weight before conception. However, much less is known about how a father's nutritional status may influence childhood health outcomes.  Based on studies in animals, exposure to undernutrition, high-fat diet, or stressful experiences in fathers can result in increased risk of obesity and diabetes in the offspring. These effects are mediated in part by epigenetic mechanisms (i.e. changes in gene expression due to differences in DNA methylation, histones, or other non-genetic mechanisms).
Alcohol, Author Interviews, Heart Disease, NEJM / 02.01.2020

MedicalResearch.com Interview with: [caption id="attachment_52609" align="alignleft" width="200"]Professor Peter M Kistler MBBS, PhD, FRACP Head of Clinical Electrophysiology Research Baker Heart and Diabetes Institute Head of Electrophysiology at The Alfred hospital Professor of Medicine University of Melbourne. Dr. Kistler[/caption] Professor Peter M Kistler MBBS, PhD, FRACP Head of Clinical Electrophysiology Research Baker Heart and Diabetes Institute Head of Electrophysiology at The Alfred hospital Professor of Medicine University of Melbourne. MedicalResearch.com: What is the background for this study? Response: There is a well known association between alcohol intake and atrial fibrillation form population based studies which demonstrate that for every 1 standard drink the incidence of AFib increases by 8%. This is the first randomised study to determine of alcohol reduction/abstinence leads to a reduction in AFib episodes and time to recurrence.
Author Interviews, Health Care Systems, JAMA / 30.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52591" align="alignleft" width="160"]Maryam Guiahi MD, MSc Associate Professor of Obstetrics and Gynecology University of Colorado Denver School of Medicine Dr. Guiahi[/caption] Maryam Guiahi MD, MSc Associate Professor of Obstetrics and Gynecology University of Colorado Denver School of Medicine MedicalResearch.com: What is the background for this study? Response: The composition of the U.S health care system is shifting; between 2001 to 2016 the number of Catholic-owned or affiliated health facilities grew by 22% in contrast to the overall number of acute care hospitals that decreased by 6% and the number of other nonprofit religious hospitals that decreased by 38%. This is relevant as Catholic health care systems enforce religious directives that restrict many aspects of reproductive care and certain aspects of end-of-life care.  Yet little is known about the extent to which U.S. patients consider religious affiliation when selecting a health care facility. 
Author Interviews, Opiods, Surgical Research / 30.12.2019

MedicalResearch.com Interview with: Sunil Agarwal, MD Michigan Opioid Prescribing Engagement Network Ann Arbor, MI MedicalResearch.com: What is the background for this study? Response: Excess opioid prescribing after surgery often leads to misuse and diversion into the community. To prevent excessive prescribing for acute pain, 31 states have implemented legislation that limits the duration of opioid prescriptions. Our study examined the effect of prescribing limits and postoperative opioid prescribing on surgical patients in Massachusetts and Connecticut, the first two states to implement opioid prescribing limits for acute pain after the CDC guidelines were released. 
Author Interviews, Heart Disease, NEJM / 28.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52605" align="alignleft" width="200"]Dr. Tardif Dr. Tardif[/caption] Jean-Claude Tardif CM, MD, FRCPC, FCCS, FACC, FAHA, FESC, FCAHS Director, Montrel Heart Institute Research Center Professor of medicine Canada Research Chair in translational and personalized medicine University of Montreal endowed research chair in atherosclerosis Montreal Heart Institute MedicalResearch.com: What is the background for this study? Response: Inflammation appears to play an important role in atherosclerosis. Inhibition of interleukin-1ß by canakinumab reduced the rate of cardiovascular events by 15% CANTOS. In contrast, methotrexate did not affect cardiovascular outcomes or plasma markers of inflammation in CIRT. Colchicine is an inexpensive, orally administered, potent anti-inflammatory medication that has been used for centuries. Colchicine is currently indicated for the management of patients with gout, familial Mediterranean fever and pericarditis. In the LODOCO study, patients with stable coronary disease treated with colchicine 0.5 mg once daily experienced fewer cardiovascular events as compared with those not receiving colchicine. However, that study enrolled only 532 patients and was not placebo-controlled. Because acute coronary syndromes are associated with higher risks of recurrent events and exacerbated inflammation, we conducted the COLchicine Cardiovascular Outcomes Trial (COLCOT) in patients with a recent myocardial infarction to evaluate the effects of colchicine on cardiovascular outcomes and its long-term safety and tolerability.
Author Interviews, JAMA, Sleep Disorders / 28.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52595" align="alignleft" width="200"]Margaret Moline, PhD Lemborexant International Program Lead and Global Medical Lead Executive Director, Neurology Business Group Eisai, Inc. Dr. Moline[/caption] Margaret Moline, PhD Lemborexant International Program Lead and Global Medical Lead Executive Director, Neurology Business Group Eisai, Inc.  MedicalResearch.com: What is the background for this study? This study, called SUNRISE 1, is one of two pivotal Phase 3 studies in the lemborexant clinical development program that supported the recent FDA approval of DAYVIGO (lemborexant).
  • On December 20, the U.S. Food and Drug Administration (FDA) approved DAYVIGO (lemborexant) 5 mg and 10 mg, an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, which is characterized by difficulties with sleep onset and/or sleep maintenance.1
  • DAYVIGO will be commercially available following scheduling by the DEA, which is expected to occur within 90 days.
  • SUNRISE 1 was a one-month, randomized, double-blind, placebo- and active-controlled, multi-center, parallel-group clinical trial in adult female patients age 55 and older and male patients 65 years and older who met DSM-5 criteria for insomnia disorder. Patients were randomized to placebo (n=208), lemborexant 5 mg (n=266) or 10 mg (n=269), or active comparator (n=263) once nightly.1
  • The primary efficacy endpoint was the mean change in log-transformed latency to persistent sleep (LPS; defined as the number of minutes from lights off to the first 10 consecutive minutes of non-wakefulness) from baseline to end of treatment (Days 29/30), as measured by overnight polysomnography (PSG) monitoring.1
  • The pre-specified secondary efficacy endpoints in Study 2 were the mean change from baseline to end of treatment (Days 29/30) in sleep efficiency (SEF) and wake after sleep onset (WASO) measured by PSG.1
  • SUNRISE 1, lemborexant 5 mg and 10 mg demonstrated statistically significant superiority on the primary efficacy measure, LPS, compared to placebo. lemborexant 5 mg and 10 mg demonstrated statistically significant improvement in SEF and WASO compared to placebo.1
  • The effects of lemborexant at the beginning of treatment were generally consistent with later timepoints.
Author Interviews, JAMA, Orthopedics, Vitamin D / 26.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52550" align="alignleft" width="200"]Robert Clarke MD, FRCP, FFPH, FFPHI, MSc, DCH Professor of Epidemiology and Public Health Medicine Clinical Trial Service Unit (CTSU) Nuffield Department of Population Health University of Oxford Dr. Clarke[/caption] Robert Clarke MD, FRCP, FFPH, FFPHI, MSc, DCH Professor of Epidemiology and Public Health Medicine Clinical Trial Service Unit (CTSU) Nuffield Department of Population Health University of Oxford MedicalResearch.com: What is the background for this study? Response: Approximately 1 in 2 women and 1 in 5 men aged 50 years or older will suffer from an osteoporotic fracture in their remaining lifetime. Hip fracture is the most serious type of osteoporotic fracture with an approximately 30% risk of death in the year following a hip fracture. Vitamin D is essential for optimal musculoskeletal health by promotion of calcium absorption, and mineralisation of osteoid tissue formation in bone and maintenance of muscle function. Low vitamin D status causes secondary hyperparathyroidism, bone loss and muscle weakness. Observational studies have reported that lower blood concentrations of vitamin D are associated with higher risks of falls and fractures. Combined supplementation with 800 IU/day vitamin D and 1200 mg/day calcium has been recommended for prevention of fractures in older adults living in institutions and in those with low vitamin D status. However, previous trials and meta-analyses of vitamin D alone, or in combination with calcium for prevention of fracture in either community-dwelling or general population settings reported conflicting results, with some reporting protective effects against fractures, but others demonstrated no beneficial effects. However, most of the previous trials had only limited power to detect differences in risk of fracture predicted by the observational studies, largely because of a combination of small sample size, relatively low equivalent daily doses of vitamin D, intermittent dosing regimens (>1 month), and short duration of follow-up. In addition, interpretation of the results of previous meta-analyses of such trials is complicated by use of variable inclusion criteria, inappropriate statistical methods, inclusion of multiple small trials with very few fracture events, in addition to failure to report achieved differences in blood 25(OH)D concentrations. We summarised the available evidence to guide clinical practice and future research, by conducting parallel meta-analyses of:
  • (i) observational studies of risks of fracture associated with prolonged differences in blood concentrations of 25(OH)D;
  • (ii) randomised trials of vitamin D alone versus placebo or no treatment for prevention of fracture; and
  • (iii) randomised trials of calcium and vitamin D versus placebo or no treatment for prevention of fracture.In addition, we reviewed the design of the ongoing randomised trials assessing the effects of higher doses of vitamin D alone or in combination with calcium for prevention of fracture.
Annals Internal Medicine, Author Interviews, Biomarkers, Heart Disease / 23.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52542" align="alignleft" width="150"]Dr. PJ Devereaux MD, PhD, FRCP(C) Director of the Division of Cardiology Scientific Leader, Anesthesiology, Perioperative Medicine, and Surgical Research Group Population Health Research Institute McMaster University Dr. Devereaux[/caption] Dr. PJ Devereaux MD, PhD, FRCP(C) Director of the Division of Cardiology Scientific Leader Anesthesiology, Perioperative Medicine, and Surgical Research Group Population Health Research Institute McMaster University  MedicalResearch.com: What is the background for this study? Response: There is an ethical obligation to provide patients with an accurate estimation of the potential benefits of surgery and the potential risks, to facilitate informed decision making about the appropriateness of surgery.  There are two common approaches to risk estimation. First, physicians commonly use clinical risk indices.  Based upon a patient’s clinical history (e.g., history of prior heart attack or stroke) an estimate of perioperative risk is determined.  Research demonstrates that these clinical risk indices have suboptimal risk discrimination capabilities, and they will underestimate risk in many patients. The second approach that has commonly been used is to have patients undergo an expensive and time consuming non-invasive cardiac test (e.g., stress nuclear cardiac study).  Although these non-invasive cardiac tests can enhance risk estimation in some patients who will have a perioperative cardiac event, these tests more commonly exaggerate risk in patients who will not have a complication.
Author Interviews, Critical Care - Intensive Care - ICUs, Mental Health Research, Opiods, Pediatrics / 23.12.2019

MedicalResearch.com Interview with: Megan Land, MD, PGY 6 Pediatric Critical Care Medicine Fellowship Emory University School of Medicine MedicalResearch.com: What is the background for this study?
  • Much of the research on the opioid crisis has focused on the impact to adults; however, children and adolescents in the US are also negatively affected by the opioid epidemic.
  • The percentage of children admitted to a pediatric intensive care unit increased over the study period as the clinical effects of the opioid ingestions increased in severity.
  • The primary intent of opioid ingestions was suspected suicide attempts in adolescents resulting in increasing admissions to a psychiatric hospital.
  • Opioids associated with the highest odds of needing an intervention in an intensive care unit were methadone, fentanyl, and heroin. 
Abuse and Neglect, Alzheimer's - Dementia, Autism, Medical Imaging, Mental Health Research, MRI, Multiple Sclerosis, Neurology, Technology / 23.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52575" align="alignleft" width="156"]Sebastian Magda, Ph.D Director of Science & Engineering CorTechs Labs, Inc Dr. Sebastian Magda[/caption] Sebastian Magda, Ph.D Director of Science & Engineering CorTechs Labs, Inc MedicalResearch.com: What is the background for this study? Response: Previous studies have shown that the changes of brain structure volume and/or metabolic activity are associated with various neurological diseases. We have created an artificial intelligence clinical decision support tool based on brain volumetric and PET metabolic activity measurements as well as other clinical measurements.
AACR, Author Interviews, Cancer Research, Ovarian Cancer / 23.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52571" align="alignleft" width="133"]Rugang Zhang, Ph.D Professor & Co-Leader, Gene Expression & Regulation Program Deputy Director, The Wistar Institute Cancer Center Dr. Zhang[/caption] Rugang Zhang, Ph.D Professor & Co-Leader, Gene Expression & Regulation Program Deputy Director, The Wistar Institute Cancer Center MedicalResearch.com: What is the background for this study? Response: Although the majority of epithelial ovarian cancer (EOC) patients initially respond well to platinum therapy, relapse ultimately occurs, which remains a major challenge in the clinical management of EOC. Substantial evidence suggests that cancer stem-like cells (CSC) contribute to chemotherapy resistance and elimination of CSC prevents the therapeutic relapse including in EOCs. Thus, therapeutic elimination of EOC CSCs represents a promising approach to achieve a durable therapeutic outcome by preventing chemotherapy resistance. Platinum-based chemotherapies are known to induce senescence that limits the propagation of cells subjected to insults such as cancer chemotherapeutics. In contrast to apoptosis, senescent cells remain viable. Senescent cells secrete a plethora of pro-inflammatory cytokines and chemokines, which is termed senescence-associated secretory phenotype (SASP). Therapy-induced inflammation promotes tumor progression and therapy resistance, and the SASP is known to promote cancer stem-like cells. However, clinically applicable approaches to target stemness associated with therapy-induced senescence remain to be explored. 
Aging, Alzheimer's - Dementia, Author Interviews, MRI, Technology / 23.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52568" align="alignleft" width="200"]Dr. Weidong Luo Principal Scientist CorTechs Labs Dr. Weidong Luo[/caption] Dr. Weidong Luo Principal Scientist CorTechs Labs  MedicalResearch.com: What is the background for this study? Response: We were interested in whether or not we can predict the age of the brain accurately from T1 weighted MRI and/or fluorodeoxyglucose (FDG) PET scans using the brain volumetric and the relative metabolic activity. The uptake of FDG is a clinical marker used to measure the uptake of glucose and therefore metabolism. Also, we were interested in the patterns of the predicted ages for Alzheimer's disease (AD) and minor cognitive impairment (MCI) subjects when using their brain measurements for age prediction in the normal brain age model.  
Author Interviews, Biomarkers, Cancer Research / 21.12.2019

MedicalResearch.com Interview with: https://www.kariusdx.com/ Dr. Asim Ahmed MD co-author of the study Senior medical director at Karius  MedicalResearch.com: What is the background for this study? Would you briefly explain the basis of the Karius Test? Response: The Karius Test is a non-invasive blood test that uses next-generation sequencing of microbial cell-free DNA to rapidly detect over 1,400 bacteria, DNA viruses, fungi, and other pathogens. Doctors primarily use the test to detect specific causative pathogens, complicated pneumonia, cardiovascular infections, and infections in immunocompromised hosts. The Karius Test is transforming how doctors diagnose infectious diseases by helping doctors identify the precise pathogens infecting patients. The Karius Test offers a higher diagnostic yield and faster time-to-diagnosis than conventional tests - with the potential to eliminate invasive diagnostic procedures like biopsies.
Author Interviews, Cancer Research / 20.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52539" align="alignleft" width="150"]Jennifer L Marti MD FACS Assistant Professor of Surgery, Breast & Endocrine Surgery Weill Cornell Medicine, New York, NY Dr. Marti[/caption] Jennifer L Marti MD FACS Assistant Professor of Surgery, Breast & Endocrine Surgery Weill Cornell Medicine, New York, NY Luc GT Morris MD, Co-senior author Head & Neck Surgery MSKCC, New York, NY MedicalResearch.com: What is the background for this study? Response: The incidence of thyroid cancer has increased dramatically over the past 3 decades. There is controversy whether this increased incidence is due to increased detection of an existing reservoir of disease, versus a true increase in the occurrence of the disease, due to an environmental carcinogen or other factors (eg obesity).
Author Interviews, Infections / 20.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52559" align="alignleft" width="150"]Dr. Konstans Wells, PhD Dr. Wells[/caption] Konstans Wells, PhD Lecturer in Biosciences Swansea University  MedicalResearch.com: What is the background for this study? Response:  Cross‐species transmission of harmful viruses between animals and humans is a major source of infectious diseases and a considerable global public health burden. We assessed patterns of virus sharing among a large diversity of mammals, including humans and domestic species.
Author Interviews, C. difficile, Gastrointestinal Disease / 20.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52518" align="alignleft" width="125"]Sarah W. Baron, M.D Assistant Professor Division of Hospital Medicine Department of Medicine, Montefiore Medical Center Bronx, New York Dr. Baron[/caption] Sarah W. Baron, M.D Assistant Professor Division of Hospital Medicine Department of Medicine, Montefiore Medical Center Bronx, New York  MedicalResearch.com: What is the background for this study? Response: We know that C. difficile can be a deadly and highly infectious disease but that it has been difficult to control. We also know that some people carry C. difficile in their body without symptoms but can still spread the organism or become sick with it themselves at some point in the future. This study attempted to answer two main questions: 1. First, how many patients coming into a large, urban academic medical center carried the organism C. difficile without any symptoms and 2. How many of those carriers without symptoms then went on to have the symptoms of C. difficile within 6 months?
Author Interviews, Heart Disease / 20.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52488" align="alignleft" width="133"]Shiwani Mahajan, MBBS Postdoctoral Associate Yale/YNHH Center for Outcomes Research and Evaluation (CORE) New Haven, CT 06510 Dr. Mahajan[/caption] Shiwani Mahajan, MBBS Postdoctoral Associate Yale/YNHH Center for Outcomes Research and Evaluation (CORE) New Haven, CT 06510  MedicalResearch.com: What is the background for this study? Response: Although the mortality rates among patients hospitalized for myocardial infarction (MI) have seen a decreasing trend, patients with MI continue to have a delayed presentation to the hospital and a large number of them die before reaching the hospital. One critical aspect of lowering mortality associated with MI is ensuring timely access to lifesaving emergency cardiac care, for which prompt recognition of symptoms of a MI and appropriate rapid emergency response are crucial. As such, in this study, we used nationally representative data to estimate awareness of 5 common symptoms of a MI (including chest pain or discomfort; shortness of breath; pain or discomfort in arms or shoulders; feeling weak or lightheaded; and jaw or neck or back pain), and the appropriate response to a MI (i.e. calling emergency medical services), among adults in the US.
Alzheimer's - Dementia, Author Interviews, Environmental Risks / 20.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52554" align="alignleft" width="200"]Professor Esme Fuller-Thomson, PhD Director of the Institute for Life Course & Aging, Factor-Inwentash Faculty of Social Work Cross-appointed to the Faculty of Medicine University of Toronto Canada Dr. Fuller-Thomson[/caption] Professor Esme Fuller-Thomson, PhD Director of the Institute for Life Course & Aging, Factor-Inwentash Faculty of Social Work Cross-appointed to the Faculty of Medicine University of Toronto Canada MedicalResearch.com: What is the background for this study? Response: Several studies from the US, Canada, and Europe suggest a promising downward trend in the incidence and prevalence of dementia. Important risk factors for dementia, such as mid-life obesity and mid-life diabetes, have been increasing rapidly, so the decline in dementia incidence is particularly perplexing.
Author Interviews, Cannabis, JAMA, Pediatrics / 20.12.2019

MedicalResearch.com Interview with: [caption id="attachment_51463" align="alignleft" width="165"]Hongying (Daisy) Dai, PhD Associate Professor Department of Biostatistics | College of Public Health University of Nebraska Medical Center Omaha Dr. Hongying (Daisy) Dai[/caption] Hongying (Daisy) Dai, PhD Associate Professor Department of Biostatistics | College of Public Health University of Nebraska Medical Center  MedicalResearch.com: What is the background for this study? Response: E-cigarette use increased significantly from 2017 to 2019 among U.S. adolescents, and marijuana and other substances besides can be used in e-cigarettes. Meanwhile, restrictions on marijuana use have been relaxing and social acceptability of marijuana use is shifting among youth. This study analyzed 38,061 middle and high school students from the 2017 and 2018 National Youth Tobacco Survey. 
Author Interviews, Dermatology / 20.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52548" align="alignleft" width="200"]Dr Kim Kjoeller MD Executive Vice President, Global Research & Development LEO Pharm Dr. Kjoeller[/caption] Dr Kim Kjoeller MD Executive Vice President, Global Research & Development LEO Pharm Discusses the recent announcement from  LEO Pharma A/S that tralokinumab  met all primary and secondary endpoints in its three Phase 3 studies (ECZTRA 1-3) for the treatment of moderate-to-severe atopic dermatitis in adults. MedicalResearch.com: What is the background for this study? Would you briefly explain what is meant by Atopic Dermatitis? Response: Atopic Dermatitis (AD) – also known as ‘atopic eczema’ – is a chronic, inflammatory, heterogeneous skin disease characterized by intense itch and eczematous lesions is the most common inflammatory skin disease in the world, with limited effective treatment options, especially for moderate-to-severe patients. The primary objective of these studies was to evaluate the efficacy of tralokinumab compared with placebo in treating moderate-to-severe atopic dermatitis.
  • ECZTRA 1 and 2 evaluated the use of tralokinumab as monotherapy
  • ECZTRA 3 evaluated the use of tralokinumab in combination with a topical corticosteroid (TCS).
Author Interviews, Breast Cancer, Weight Research / 19.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52536" align="alignleft" width="136"]Lauren Teras, PHD Scientific Director, Epidemiology Research American Cancer Society Dr. Teras[/caption] Lauren Teras, PHD Scientific Director, Epidemiology Research American Cancer Society MedicalResearch.com: What is the background for this study? Response: Excess body weight is a known cause of postmenopausal breast cancer, but an important question is: can you reverse it? Believe it or not, this not something we knew for certain. We had hoped it was true, but the scientific evidence was not there. This research question is, of course, particularly important for the more than two-thirds of U.S. women who are overweight or obese, and therefore at higher risk for breast cancer. To try to answer this question, we used a very large pooled study of 180,000 women aged ≥50 years from 10 different prospective studies. 
AACR, Author Interviews, Cancer Research / 19.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52532" align="alignleft" width="130"]Dr. Samir Parekh, MBBS Associate Professor Medicine, Hematology and Medical Oncology Icahn School of Medicine at Mount Sinai Dr. Parekh[/caption] Dr. Samir Parekh, MBBS Associate Professor Medicine, Hematology and Medical Oncology Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? Would you briefly describe what is meant by 'neoantigens'? How might they be used to stimulate immunity in a multiple myeloma patients?  Response: Myeloma is considered a “cold” tumor for immunotherapy (as compared to some solid tumors such as melanoma) given the relatively fewer DNA mutations in an average myeloma patient. Our clinical experience suggests that this may not be totally correct.  Our findings focus on mutations that can become antigens (neo-antigens) and challenges the stereotype. We can create vaccines based on peptides resulting from these mutations to stimulate immune responses.
Author Interviews, Epilepsy / 19.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52529" align="alignleft" width="160"]Steve S. Chung MD Epilepsy Neurology Banner University Medical Center University of Arizona, Phoenix, AZ Dr. Chung[/caption] Steve S. Chung MD Epilepsy Neurology Banner University Medical Center University of Arizona, Phoenix, AZ MedicalResearch.com: What is the background for this study? Response: Prior studies have shown that midazolam nasal spray (MDZ-NS) is superior to placebo in providing rapid, sustained seizure control and a favorable safety profile when administered to patients experiencing seizure clusters, a type of seizure emergency impacting an estimated 150,000 patients in the U.S. with uncontrolled epilepsy. To explore the influence of concomitant antiepileptic drugs (AEDs) on treatment outcomes, we conducted a post hoc analysis of a Phase III trial to evaluate the tolerability and efficacy of midazolam nasal spray in patients 12 years of age and older with seizure clusters, according to concomitant enzyme-inducing AED (EIAED)/non-enzyme-inducing AED (NEIAED) status and by the number of concomitant AEDs.
Author Interviews, Epilepsy / 19.12.2019

MedicalResearch.com Interview with: [caption id="attachment_52524" align="alignleft" width="200"]Eun Jung Choi, MD, PhD; Senior Director, New Product Launch, Neurology UCB Dr. Eun Jung Choi[/caption] Eun Jung Choi, MD, PhD; Senior Director, New Product Launch, Neurology UCB MedicalResearch.com: What is the background for this study? Response: Patients experiencing seizure clusters, a type of seizure emergency impacting an estimated 150,000 patients in the U.S. with uncontrolled epilepsy, are at risk for potentially serious consequences including hospitalization, mortality, physical injury, neurological damage, and status epilepticus. Although unmet needs of seizure clusters are intuitively well accepted, the burden of seizure clusters has not been well characterized and evaluated in a systemic matter. As a result, the seizure cluster patients are overlooked, and burden of seizure clusters is under-recognized. So we systematically assessed the clinical, humanistic, and economic burden associated with seizure clusters to provide the comprehensive body of evidence about burden of seizure clusters.